TY - JOUR T1 - Evaluation of efficacy of interferon inducer in treatment of the recurrent acute respiratory viral infections in children JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P1914 AU - Andrey Zaplatnikov AU - Nina Korovina AU - Irina Zakharova AU - Elena Burtseva AU - Gulfia Mingalimova AU - Ludmila Zaplatnikova AU - Irina Zak AU - Ludmila Shamrai Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P1914.abstract N2 - Background: It is known that recurrent episodes of acute respiratory viral infections (recurrent ARVI) are common for children attending nursery school. Nowadays the opportunities of multiple use of interferon inducer (IFN-i) in treatment of ARVI are unknown.Aim: To evaluate the efficacy and safety of IFN-i (anaferon) in treatment of recurrent ARVI in children attending nursery school.Methods: The open comparative prospective 2-center clinical trial of efficacy in parallel groups was conducted. The trial was performed in 141 children at the age of 1-5 years. 75 children included in 1-st group received IFN-i in preventive regimen: 1 pill 1 time in a day for 3 months. The 2-d group consisted of 16 children and they didn't receive medical prevention of ARVI. In case of appearing the ARVI symptoms all children received symptomatic medicines and the children of 1-st group received IFN-i in treatment regimen (1 pill 3 times in a day for 5 days, in first day additionally 5 pills). The duration of the first and recurrent episodes of ARVI in groups were estimated.Results: The mean duration of ARVI was 8,9±0,92 days in 1-st group, and 14,6±1,79 days in control group respectively. The duration of the first ARVI episode was 8,9±1,12 and 15,8±2,1 days in 1-st and 2-d groups respectively. The duration of the second ARVI episode was 8,1±0,78 in 1-st group vs 14,2±2,11 days in 2-d groups. There were not registered any adverse effects in a children taking IFN-i during the trial.Conclusions: The use of IFN-i (anaferon) in treatment of ARVI leads to reduction of disease duration. In case of repeated anaferon administration its treatment efficacy isn't decreased. ER -